Acarix A/S - Asset Resilience Ratio

Latest as of December 2025: 37.81%

Acarix A/S (ACARIX) has an Asset Resilience Ratio of 37.81% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Acarix A/S (ACARIX) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

Skr18.27 Million
≈ $1.97 Million USD Cash + Short-term Investments

Total Assets

Skr48.33 Million
≈ $5.20 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Acarix A/S's Asset Resilience Ratio has changed over time. See shareholders equity of Acarix A/S for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Acarix A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Acarix A/S (ACARIX) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr18.27 Million 37.81%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr18.27 Million 37.81%

Asset Resilience Insights

  • Very High Liquidity: Acarix A/S maintains exceptional liquid asset reserves at 37.81% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Acarix A/S Industry Peers by Asset Resilience Ratio

Compare Acarix A/S's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Demant A/S
CO:DEMANT
Medical Devices -2.59%
Double Medical Technology Inc
SHE:002901
Medical Devices 7.79%
Beijing Wandong Medical Technology Co Ltd
SHG:600055
Medical Devices 4.92%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
MODULIGHT OY EO 1
F:78W
Medical Devices 22.31%
Diagnostic Medical Systems SA
PA:ALDMS
Medical Devices 1.39%
Theradiag SA
PA:ALTHE
Medical Devices 15.59%
Nova EYE Medical Ltd
AU:EYE
Medical Devices 11.08%

Annual Asset Resilience Ratio for Acarix A/S (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Acarix A/S.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.19% Skr152.00K
≈ $16.36K
Skr80.76 Million
≈ $8.69 Million
-0.05pp
2023-12-31 0.23% Skr147.00K
≈ $15.82K
Skr62.88 Million
≈ $6.77 Million
-16.04pp
2022-12-31 16.28% Skr11.31 Million
≈ $1.22 Million
Skr69.48 Million
≈ $7.48 Million
+2.79pp
2021-12-31 13.49% Skr16.00 Million
≈ $1.72 Million
Skr118.60 Million
≈ $12.76 Million
+13.27pp
2020-12-31 0.22% Skr195.00K
≈ $20.99K
Skr89.95 Million
≈ $9.68 Million
-0.07pp
2019-12-31 0.28% Skr234.00K
≈ $25.18K
Skr82.98 Million
≈ $8.93 Million
-68.19pp
2018-12-31 68.48% Skr65.19 Million
≈ $7.02 Million
Skr95.20 Million
≈ $10.24 Million
-8.79pp
2017-12-31 77.27% Skr103.58 Million
≈ $11.15 Million
Skr134.06 Million
≈ $14.43 Million
-6.97pp
2016-12-31 84.24% Skr145.97 Million
≈ $15.71 Million
Skr173.29 Million
≈ $18.65 Million
+83.89pp
2015-12-31 0.35% Skr54.00K
≈ $5.81K
Skr15.58 Million
≈ $1.68 Million
--
pp = percentage points

About Acarix A/S

ST:ACARIX Sweden Medical Devices
Market Cap
$33.84 Million
Skr314.47 Million SEK
Market Cap Rank
#23306 Global
#445 in Sweden
Share Price
Skr0.27
Change (1 day)
-2.88%
52-Week Range
Skr0.20 - Skr0.43
All Time High
Skr20.62
About

Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauri… Read more